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1. Introduction {#jia225034-sec-0005}
===============

Human immunodeficiency virus (HIV) affects over 36.7 million people worldwide [1](#jia225034-bib-0001){ref-type="ref"}, [2](#jia225034-bib-0002){ref-type="ref"}. Nearly, half of those infected with HIV remain untreated, increasing their risks for acquired immune deficiency syndrome (AIDS), onward HIV transmission and mortality [3](#jia225034-bib-0003){ref-type="ref"}, [4](#jia225034-bib-0004){ref-type="ref"}, [5](#jia225034-bib-0005){ref-type="ref"}. While not a cure, antiretroviral therapy (ART) has substantially benefitted more than 18 million people infected with HIV for over two decades by controlling viral replication, AIDS and non‐AIDS events, and by reducing the risk of transmission [6](#jia225034-bib-0006){ref-type="ref"}, [7](#jia225034-bib-0007){ref-type="ref"}. However, the existence of latent viral reservoirs in CD4 T cells remains a hurdle to curing HIV infection and patients must remain on ART for the rest of their lives [2](#jia225034-bib-0002){ref-type="ref"}. We and others have reported that the predictors of HIV reservoir size include the nadir CD4 T cell count [8](#jia225034-bib-0008){ref-type="ref"}, CD4/CD8 ratio [9](#jia225034-bib-0009){ref-type="ref"}, the level of immune activation and the timing of initiation and duration of ART [10](#jia225034-bib-0010){ref-type="ref"}, [11](#jia225034-bib-0011){ref-type="ref"}, [12](#jia225034-bib-0012){ref-type="ref"}. In addition, early ART initiation has also been linked to normalization of CD8 T cell counts, further reducing the risk of non‐AIDS events [13](#jia225034-bib-0013){ref-type="ref"}.

Historically, decisions to initiate ART have been based on AIDS‐related clinical events, CD4 T‐cell count and comorbidities while trying to limit the risk of drug resistance and reduce ART‐related lipodystrophy and other toxicities [14](#jia225034-bib-0014){ref-type="ref"}, [15](#jia225034-bib-0015){ref-type="ref"}, [16](#jia225034-bib-0016){ref-type="ref"}, [17](#jia225034-bib-0017){ref-type="ref"}. Until 2008, treatment guidelines from the World Health Organization (WHO), Department of Health and Human Services (DHHS) USA, the European AIDS Clinical Society (EACS) and International AIDS Society (IAS) recommended ART initiation at CD4 count\<350 cells/mm^3^ [6](#jia225034-bib-0006){ref-type="ref"}, [18](#jia225034-bib-0018){ref-type="ref"}, [19](#jia225034-bib-0019){ref-type="ref"}, [20](#jia225034-bib-0020){ref-type="ref"}. However, with the availability of more potent and tolerable ART, as well as data from the INSIGHT START and TEMPRANO studies [21](#jia225034-bib-0021){ref-type="ref"}, [22](#jia225034-bib-0022){ref-type="ref"}, early ART regardless of CD4 count is now uniformly recommended [1](#jia225034-bib-0001){ref-type="ref"}, [23](#jia225034-bib-0023){ref-type="ref"}, [24](#jia225034-bib-0024){ref-type="ref"}. CD4 count, therefore, is decreasingly considered a factor for treatment initiation and can be used as marker of a patient\'s immune and clinical status and prognosis [25](#jia225034-bib-0025){ref-type="ref"}.

ART initiation has also been linked to a variety of socio‐demographic and behavioural characteristics [26](#jia225034-bib-0026){ref-type="ref"}, [27](#jia225034-bib-0027){ref-type="ref"}, even in the context of publicly funded health care and medication access [28](#jia225034-bib-0028){ref-type="ref"}, [29](#jia225034-bib-0029){ref-type="ref"}, [30](#jia225034-bib-0030){ref-type="ref"}, [31](#jia225034-bib-0031){ref-type="ref"}. For instance, studies conducted in several African countries have shown that older age, female sex, pregnancy, lower psychological distress, no perceived communication barriers with providers and a gap in care of less than six months were associated with early ART initiation [26](#jia225034-bib-0026){ref-type="ref"}, [27](#jia225034-bib-0027){ref-type="ref"}. In 133 injecting drug users (IDUs) recruited in observational cohorts in Vancouver, Canada, Joseph *et al*. showed that recent calendar year and supervised methadone use were associated with early ART initiation whereby informal income generation and incarceration were associated with delayed ART initiation [28](#jia225034-bib-0028){ref-type="ref"}. Moreover, Cescon *et al*. observed that late ART initiation was more likely among females, non‐MSM and older age in 8942 participants in the Canadian Observational Cohort Study (CANOC) [29](#jia225034-bib-0029){ref-type="ref"}.

Understanding the various potential correlates of early ART initiation is important for informing ongoing and future care interventions. This understanding may also contribute towards achieving the Joint United Nations Program on HIV/AIDS (UNAIDS)\'s ambitious goal for global ART programs, referred to as the 90‐90‐90 targets by the year 2020 [32](#jia225034-bib-0032){ref-type="ref"}, [33](#jia225034-bib-0033){ref-type="ref"}. To this end, the Canadian statistics of 2014 report that an estimated 80% (73% to 87%) of persons living with HIV had been diagnosed, 76% (70% to 82%) of persons diagnosed with HIV were on treatment, and 89% (84% to 93%) of persons on treatment had suppressed viral load (VL) [34](#jia225034-bib-0034){ref-type="ref"}. Since increasing numbers of people will be offered ART over the long‐term, a better understanding of the factors playing a role in ART initiation may unveil potential barriers to overcome. Therefore, this study aimed to determine the role of socio‐demographic, socio‐economic, behavioural and clinical factors in early ART initiation during primary HIV infection (PHI) in Montreal, a setting where publicly funded universal health care and medication insurance are provided [35](#jia225034-bib-0035){ref-type="ref"}.

2. Methods {#jia225034-sec-0006}
==========

2.1. Study design and population {#jia225034-sec-0007}
--------------------------------

Established in 1996 at the time of onset of combination ART, the Montreal PHI Study [13](#jia225034-bib-0013){ref-type="ref"}, [36](#jia225034-bib-0036){ref-type="ref"} is a cohort of early HIV‐1 infected individuals aged 18 years and above who are followed by physicians at either three community medical centres (CMCs) or at two university‐affiliated medical centres (UMCs). This flexibility allows participation of people who inject drugs (PWID) as universal access to care is provided by the Canadian healthcare system. Participants with an estimated date of HIV acquisition of less than 180 days were included and followed initially every three months for 24 months, with follow‐up being extended to 48 months in 2008. HIV diagnosis and ascertainment of PHI was performed using the guidelines proposed by the DHHS‐NIH Acute HIV Infection and Early Diagnosis Research Program [24](#jia225034-bib-0024){ref-type="ref"} as described previously [37](#jia225034-bib-0037){ref-type="ref"}. Briefly, acute HIV‐1 infection (AHI) is defined as negative HIV p24 antibody testing by enzyme‐linked immunosorbent assay (ELISA) in the presence of detectable HIV‐1 RNA or positive HIV p24 antibody testing by ELISA and an evolving (≤3 bands positive) HIV Western blot. Early HIV‐1 infection (EHI) is defined by documented HIV‐1 acquisition within the previous six months. The HIV diagnosis and date of HIV acquisition was ascertained by a physician specialized in HIV at the participating study sites. The term PHI used in this study refers to both AHI and EHI. A structured case report form (CRF) was used to record the participants\' socio‐demographic, socio‐economic, behavioural and clinical characteristics at first/baseline visit and each follow‐up visit.

ART initiation guidelines devised by national or international expert panels like that of DHHS, IAS, WHO and EACS in asymptomatic HIV‐infected adults varied during the study period as recently reviewed by Eholie *et al*. [38](#jia225034-bib-0038){ref-type="ref"}. Briefly, in late 1990s, the guidelines in the absence of evidence from randomized clinical trials (RCTs), recommended to start treatment at CD4 count of ≤500/mm^3^, which then dropped to CD4 count of ≤200 at the beginning of the 2000s owing to the growing concerns of long‐term drug toxicity. With the availability of data from early RCTs in 2006, this threshold was set at CD4 count of ≤350/mm^3^ for a brief period to reduce the higher risk of severe morbidity. This threshold was than increased to CD4 count of ≤500/mm^3^ by most panels during 2009 and 2013 and finally treatment for all patients was recommended since 2015.

2.2. Early versus late ART {#jia225034-sec-0008}
--------------------------

The initiation of ART during follow‐up was recorded during subsequent visits at a maximum interval of three months. This binary outcome was defined as initiation of ART within 180 days of the first/baseline visit.

2.3. Socio‐demographic, socio‐economic and behavioural factors {#jia225034-sec-0009}
--------------------------------------------------------------

The baseline socio‐demographic factors evaluated for their association with early ART initiation included age (years), sex (male vs. female), born in Canada (yes vs. no), ethnic background (Caucasian vs. non‐Caucasians) and mode of living (living alone vs. as a couple, with family and others). Socio‐economic factors included source of revenue (paid employment vs. on social welfare or unemployment benefits), personal annual income in Canadian dollars (below 10,000, 10,000 to 29,999, 30,000 to 49,999 vs. 50,000 and above) and more than elementary education (yes vs. no). Information on behavioural factors included exposure group (heterosexual, PWID, MSM vs. dual exposure group: that is, heterosexual and PWID) and number of sexual partners in past three months (zero, one to four vs. more than or equal to five partners).

2.4. Clinical factors {#jia225034-sec-0010}
---------------------

Testing for HIV‐1 p24 antigen and testing for HIV‐1 antibodies by EIA were performed in laboratories of the participating university‐affiliated medical centres. Confirmatory testing by Western blot was performed for all samples at the Laboratoire de Santé Publique du Québec. The ARCHITECT HIV Ag/Ab Combo assay was used for concurrent testing of p24 antigen and HIV‐1 antibodies after 2011 (Abbott Laboratories, Abbott Park, IL, USA). Laboratory testing also included measurements of plasma VL, CD4 and CD8 counts. Plasma VL was measured using the Roche Amplicor HIV Monitor assay (Roche Diagnostics, Mississauga, Ontario, Canada) until 2010 or the Abbott RealTime HIV‐1 assay (Abbott Laboratories) onwards.

2.5. Statistical analyses {#jia225034-sec-0011}
-------------------------

Descriptive analyses were performed with means and standard deviations calculated for the variables with normal distribution and the median with interquartile range (IQR) calculated for variables with non‐normal distribution. Inferential analyses were conducted to measure the differences in socio‐demographic, socio‐economic, behavioural and clinical characteristics in association with early ART initiation at a level of significance of 5%, using bivariate logistic regression. The year of enrolment was also categorized into three‐year intervals (with the exception of the comparison group of 1996 to 1997 with a two‐year interval), which provided a robust sample size of over 35 participants in each category for further analysis. In addition, such an analysis strategy could also mitigate the potential influence of data artefacts. Mantel‐Haenszel χ^2^ test of trend was conducted for the analysis of ART initiation over years. Multivariable binary logistic regression analysis was conducted to determine the independent association of factors with early ART initiation. Using an exploratory analysis approach, all clinically relevant factors regardless of their statistical significance were simultaneously included in the multivariable model; no model reduction was performed. For two covariates that were highly correlated with each other (CD4/CD8 with CD4 and CD8; income with employment status) only one was selected; this decision was informed by consideration of missing data and clinical relevance. As the multivariable model does not consider cases with missing information, about 13.2% of such cases were only included in the univariable analysis. Interactions between year and other independent factors were assessed and were found to be insignificant (*p* \> 0.05). Box‐Tidwell test was performed to check the assumption of linearity for quantitative variables in the multivariable model. The Hosmer‐Lemeshow goodness of fit test was performed to assess the fitness of the final model, which showed a reasonable fit (*p* = 0.741). Statistical significance in the univariable and multivariable analyses was defined as a two‐tailed *p* \< 0.05. SPSS 23.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 7.0 (GraphPad Software, Inc. La Jolla, CA, USA) were used to perform and report on the statistical analyses.

2.6. Ethical considerations {#jia225034-sec-0012}
---------------------------

The Montreal PHI Study was approved by the research ethics boards of all participating sites. The study was conducted in accordance with declaration of Helsinki and all study subjects provided written informed consent for their participation in the study.

3. Results {#jia225034-sec-0013}
==========

3.1. Characteristics of study participants {#jia225034-sec-0014}
------------------------------------------

A total of 549 participants were recruited from 1996 to 2015, of which 348 (63%) were analysed as they had a documented date of HIV acquisition of \<180 days with adequate follow‐up (Figure [1](#jia225034-fig-0001){ref-type="fig"}). The majority of participants were male (96%) with a median IQR age of 35 (28; 42) years at baseline. Furthermore, the vast majority of the study participants reported being born in Canada (81%), living alone (49%) and being Caucasian (89%). Among socio‐economic factors, a majority reported having paid employment (63%), an annual income of less than or equal to 30,000 Canadian dollars (56%) and more than elementary school education (91%). MSM was the most common exposure group (78%) and a majority of participants (70%) reported one to four sexual partners in the last three months. The baseline clinical presentation included median CD4 count of 510 (387; 660) cells/μl, CD8 count of 829 (600; 1232) cells/μl, CD4/CD8 ratio of 0.6 (0.4 to 0.9) and VL of 4.6 (3.7; 5.3) log~10~ copies/ml (Table [1](#jia225034-tbl-0001){ref-type="table-wrap"}).

![Flowchart describing study population distribution.](JIA2-21-e25034-g001){#jia225034-fig-0001}

###### 

Baseline socio‐demographic, socio‐econonmic, behavioural and clinical characteristics of the study participants according to timing of ART initiation, (1996 to 2015)

  Characteristics                                                Total (n = 348)     Early ART initiation   *p*                 Bivariate OR (95% CI)[a](#jia225034-note-0003){ref-type="fn"}   Missing obs.        
  -------------------------------------------------------------- ------------------- ---------------------- ------------------- --------------------------------------------------------------- ------------------- ----
  Socio‐demographic                                                                                                                                                                                                 
  Age in years[b](#jia225034-note-0004){ref-type="fn"}           35.0 (28.0, 42.0)   37.0 (30.0, 43.0)      34.0 (27.0, 42.0)   0.015[\*](#jia225034-note-0007){ref-type="fn"}                  1.14 (1.03, 1.27)   0
  Male                                                           334 (96.0)          155 (94.5)             179 (97.3)          0.198                                                           0.48 (0.16, 1.47)   0
  Born in Canada                                                 265 (81.0)          120 (73.2)             145 (78.8)          0.480                                                           1.23 (0.70, 2.15)   21
  Caucasian                                                      311 (89.4)          141 (85.9)             170 (92.4)          0.056                                                           0.51 (0.25, 1.01)   0
  Mode of living                                                                                                                                                                                                    18
  Alone                                                          163 (49.4)          80 (48.8)              83 (45.1)           Ref.                                                            Ref.                
  Couple                                                         83 (25.2)           38 (23.2)              45 (24.5)           0.625                                                           0.88 (0.52, 1.49)   
  Family                                                         32 (9.7)            13 (7.9)               19 (10.3)           0.383                                                           0.71 (0.33, 1.53)   
  Others                                                         52 (15.8)           24 (14.6)              28 (15.2)           0.713                                                           0.89 (0.48, 1.67)   
  Socio‐economic                                                                                                                                                                                                    
  Paid employment                                                208 (62.7)          104 (63.4)             104 (56.5)          0.155                                                           1.39 (0.88, 2.17)   16
  Annual income                                                                                                                                                                                                     38
  Below 10,000\$                                                 79 (25.5)           37 (22.6)              41 (22.3)           Ref.                                                            Ref.                
  10,000 to 29,999\$                                             93 (30.0)           43 (26.2)              49 (26.6)           0.937                                                           0.98 (0.54, 1.78)   
  30,000 to 49,999\$                                             94 (30.3)           47 (28.7)              47 (25.5)           0.678                                                           1.14 (0.62, 2.07)   
  Above 50,000                                                   44 (14.2)           17 (10.4)              27 (14.7)           0.381                                                           0.72 (0.34, 1.51)   21
  More than elementary education                                 299 (91.4)          141 (86.0)             158 (85.9)          0.663                                                           1.19 (0.54, 2.60)   
  Behavioural                                                                                                                                                                                                       
  Exposure group                                                                                                                                                                                                    0
  Heterosexual                                                   27 (7.8)            18 (11.0)              9 (4.9)             Ref.                                                            Ref.                
  PWID                                                           27 (7.8)            16 (9.8)               11 (6.0)            0.574                                                           0.73 (0.24, 2.20)   
  MSM                                                            270 (77.6)          122 (74.4)             148 (80.4)          0.038[\*](#jia225034-note-0007){ref-type="fn"}                  0.41 (0.18, 0.95)   
  Dual                                                           24 (6.9)            8 (4.9)                16 (8.7)            0.020[\*](#jia225034-note-0007){ref-type="fn"}                  0.25 (0.08, 0.80)   
  Multiple partners                                                                                                                                                                                                 13
  Zero partners                                                  28 (8.4)            14 (8.5)               14 (7.6)            Ref.                                                            Ref.                
  One to four partners                                           234 (69.9)          110 (67.1)             124 (67.4)          0.765                                                           0.89 (0.41, 1.94)   
  ≥5 partners                                                    73 (21.8)           33 (20.1)              40 (21.7)           0.666                                                           0.83 (0.35, 1.97)   
  Clinical                                                                                                                                                                                                          
  CD4 count (cells/μl)[c](#jia225034-note-0005){ref-type="fn"}   510 (387, 660)      440 (333, 611)         540 (447, 683)      \<0.001[\*\*\*](#jia225034-note-0007){ref-type="fn"}            0.90 (0.86, 0.95)   5
  CD8 count (cells/μl)[d](#jia225034-note-0006){ref-type="fn"}   829 (600, 1232)     876 (589, 1276)        810 (615, 1207)     0.329                                                           1.01 (0.99, 1.02)   6
  CD4/CD8 ratio                                                  0.59 (0.38, 0.86)   0.51 (0.32, 0.82)      0.64 (0.46, 0.91)   0.255                                                           0.77 (0.49, 1.21)   6
  VL, log~10~ copies/ml                                          4.6 (3.7, 5.3)      4.8 (3.7, 5.6)         4.4 (3.7, 5.0)      0.002[\*\*](#jia225034-note-0007){ref-type="fn"}                1.36 (1.12, 1.64)   2
  Recruitment centre                                                                                                                                                                                                
  CMCs                                                           181 (52.0)          76 (46.4)              105 (57.1)          Ref.                                                            Ref.                
  UMC                                                            167 (48.0)          88 (53.7)              79 (42.9)           0.046[\*](#jia225034-note-0007){ref-type="fn"}                  1.54 (1.01, 2.35)   0

Values are median (Q1, Q3) or number of participants (%). ART, antiretroviral therapy; Ref., reference category; obs., observations; others, friends or institution; PWID, people who inject drugs; MSM, men who have sex with men; VL, viral load; UMC, university medical centre; CMC, community medical centre

^a^OR, odds ratio, 95% CI confidence interval estimated from bivariate logistic regression analyses.

^b^Age OR and 95% CI calculated per five year increase.

^c^CD4 OR and 95% CI calculated per 50 cells/μl increase.

^d^CD8 OR and 95% CI calculated per 50 cells/μl increase.

\**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.

John Wiley & Sons, Ltd

3.2. Early ART initiation, its associated factors and trends over time {#jia225034-sec-0015}
----------------------------------------------------------------------

Early treatment, which was defined as starting within 180 days of baseline visit, was initiated in approximately half of the participants (n = 164, 47%). When compared to those who did not initiate early ART, bivariate analysis demonstrated that these participants were significantly older in age (OR per five‐year increase: 1.14; 95% CI: 1.03, 1.27) with no differences observed between males versus females, being born in Canada versus outside Canada, and living alone versus other living modes (living as a couple, a family, or with friends). Socio‐economic factors were not associated with early ART initiation. Compared to participants in the heterosexual exposure group, MSM (OR: 0.41; 95% CI: 0.18, 0.95) and those in the dual exposure group (OR: 0.25; 95% CI: 0.08, 0.80) were significantly less likely to initiate early ART. Other factors significantly associated with early ART initiation in the bivariate analyses were a lower CD4 count (OR per increase of 50 cells/μl: 0.90; 95% CI: 0.86, 0.95), a higher VL (OR per log~10~ copies/ml increase in VL: 1.36; 95% CI: 1.12, 1.64) and being recruited in UMCs versus CMCs (OR: 1.54; 95% CI: 1.01, 2.35) (Table [1](#jia225034-tbl-0001){ref-type="table-wrap"}). In addition, participants at CMCs versus UMCs presented with a higher median CD4 count (530 vs. 497 cells/μl; *p* = 0.044), which may explain the 10% difference in early ART initiation between these two medical clinics (Data not shown).

The majority of early cohort (1996 to 1998) and late cohort (2012 to 2015) participants initiated early treatment, with proportions reaching approximately 90% by the years 2014 to 2015 (Figure [2](#jia225034-fig-0002){ref-type="fig"}a). However, proportions of participants initiating ART early between 2003 and 2011 remained below 40% (Figure [2](#jia225034-fig-0002){ref-type="fig"}a). We further categorized the years into three‐year intervals (with the exception of the comparison group of 1996 to 1997 having a two‐year interval). Early ART initiation was significantly associated with calendar time grouped into such three‐year intervals (χ^2^ for trend *p* = 0.004). A V‐shaped curve of early ART initiation was observed when the years were categorized by such three‐year intervals (which provided a sample size of greater than 35 participants in each category for further analysis (Figure [2](#jia225034-fig-0002){ref-type="fig"}b)). Multivariable analysis showed that having paid employment versus being on social benefits/unemployment insurance adjusted odds ratio (aOR: 2.43; 95% CI: 1.19, 4.95), lower CD4 cells/μl (aOR per 50 cell increase: 0.93; 95% CI: 0.87, 0.99), greater CD8 cells/μl (aOR per 50 cells/μl increase: 1.02; 95% CI: 1.00 to 1.04) and receiving care at UMCs versus CMCs (aOR: 2.03; 95% CI: 1.06 to 3.90) were independently associated with early ART initiation.

![(a) Trends of early ART initiation over years during primary HIV infection in Montreal; 1996 to 2015. (b) Trends of early ART initiation over three‐year intervals during primary HIV infection in Montreal; 1996 to 2015. ART, antiretroviral therapy.](JIA2-21-e25034-g002){#jia225034-fig-0002}

When compared to the years 1996 to 1997, early ART initiation was significantly less likely during the years from 1998 to 2012 independent of other factors, while it was similar for the most recent years 2013 to 2015 (aOR: 0.39; 95% CI: 0.06 to 2.36) (Table [2](#jia225034-tbl-0002){ref-type="table-wrap"}). These findings highlight that early ART initiation is not only associated with evolving treatment recommendations (prognostic factors and calendar year), but also with socio‐economic characteristics such as employment.

###### 

Multivariable analysis of factors associated with early ART initiation

  Characteristics                                                aOR    95% CI       *p*
  -------------------------------------------------------------- ------ ------------ --------------------------------------------------------
  Socio‐demographic                                                                  
  Age in years[a](#jia225034-note-0009){ref-type="fn"}           1.17   0.99, 1.39   0.055
  Male                                                           0.38   0.08, 1.96   0.249
  Born in Canada                                                 2.62   0.92, 7.44   0.071
  Caucasian                                                      0.44   0.12, 1.66   0.225
  Mode of living                                                                     
  Alone                                                          Ref.   Ref.         Ref.
  Couple                                                         0.61   0.29, 1.29   0.198
  Family                                                         0.92   0.30, 2.80   0.885
  Others                                                         1.44   0.60, 3.44   0.417
  Socio‐economic                                                                     
  Paid employment                                                2.43   1.19, 4.95   0.015[\*](#jia225034-note-0013){ref-type="fn"}
  More than elementary education                                 0.98   0.29, 3.30   0.968
  Behavioural                                                                        
  Exposure group                                                                     
  Heterosexual                                                   Ref.   Ref.         Ref.
  PWID                                                           0.45   0.07, 2.76   0.389
  MSM                                                            0.60   0.18, 2.01   0.412
  Dual                                                           0.45   0.10, 2.07   0.307
  Multiple partners                                                                  
  Zero partners                                                  Ref.   Ref.         Ref.
  One to four partners                                           1.59   0.41, 6.24   0.504
  ≥5 partners                                                    0.92   0.22, 3.80   0.906
  Clinical                                                                           
  CD4 count (cells/μl)[b](#jia225034-note-0010){ref-type="fn"}   0.93   0.87, 0.99   0.039[\*](#jia225034-note-0013){ref-type="fn"}
  CD8 count (cells/μl)[c](#jia225034-note-0011){ref-type="fn"}   1.02   1.00, 1.04   0.031[\*](#jia225034-note-0013){ref-type="fn"}
  VL, log~10~ copies/ml                                          1.21   0.89, 1.64   0.220
  Recruitment centre                                                                 
  CMCs                                                           Ref.   Ref.         Ref.
  UMC                                                            2.03   1.06, 3.90   0.033[\*](#jia225034-note-0013){ref-type="fn"}
  Calendar year[d](#jia225034-note-0012){ref-type="fn"}                              
  1996 to 1997                                                   Ref.   Ref.         Ref.
  1998 to 2000                                                   0.08   0.02, 0.37   0.001[\*\*](#jia225034-note-0013){ref-type="fn"}
  2001 to 2003                                                   0.03   0.01, 0.13   \<0.001[\*\*\*](#jia225034-note-0013){ref-type="fn"}
  2004 to 2006                                                   0.02   0.01, 0.11   \<0.001[\*\*\*](#jia225034-note-0013){ref-type="fn"}
  2007 to 2009                                                   0.01   0.00, 0.05   \<0.001[\*\*\*](#jia225034-note-0013){ref-type="fn"}
  2010 to 2012                                                   0.03   0.01, 0.17   \<0.001[\*\*\*\*](#jia225034-note-0013){ref-type="fn"}
  2013 to 2015                                                   0.39   0.06, 2.36   0.302

aOR, adjusted odds ratio, 95% CI confidence interval estimated from multivariable logistic regression analysis. ART, antiretroviral therapy; Ref., reference category; others, friends or institution; PWID, people who inject drugs; MSM, men who have with men; VL, viral load; UMC, University Medical Centre; CMC, Community Medical Centre.

^a^Age OR and 95% CI calculated per five year increase.

^b^CD4 OR and 95% CI calculated per 50 cells/μl increase.

^c^CD8 OR and 95% CI calculated per 50 cells/μl increase.

^d^Calendar year categorized per three‐year interval with the exception of reference group (1996 to 1997).

\**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.

John Wiley & Sons, Ltd

4. Discussion {#jia225034-sec-0016}
=============

Early diagnosis and prompt treatment initiation are considered key factors in controlling HIV epidemic. Based on which, UNAIDS has adopted 90‐90‐90 target that by 2020 ≥90% of persons living with HIV infection (PLWH) will know their HIV status, ≥90% of PLWH will be on ART and ≥90% will achieve viral suppression on ART [32](#jia225034-bib-0032){ref-type="ref"}. Achieving these targets by 2020 would lead to an end of the AIDS epidemic by 2030. Considered a window of opportunity, ART initiated in PHI has been associated with decreased seeding of latent reservoirs, near normalization of immune activation, reduction in the risk for progression to AIDS and non‐AIDS illnesses and a substantial reduction in the risk for secondary transmission [7](#jia225034-bib-0007){ref-type="ref"}, [10](#jia225034-bib-0010){ref-type="ref"}, [11](#jia225034-bib-0011){ref-type="ref"}, [39](#jia225034-bib-0039){ref-type="ref"}, [40](#jia225034-bib-0040){ref-type="ref"}, [41](#jia225034-bib-0041){ref-type="ref"}. PHI therefore provides the best opportunity for early ART initiation. Our study determined associations between socio‐demographic, socio‐economic, behavioural, clinical characteristics and calendar year with early ART initiation in participants of the Montreal PHI study. Nearly half of the participants initiated early ART, which was independently associated with having paid employment, lower CD4 and elevated CD8 T‐cell counts, receiving care at a UMC and remote as well as more recent calendar years. Recent trends show over 90% of participants initiating early ART, which is encouraging given the clinical and population benefits inherent in currently recommended treatment guidelines by WHO, DHHS and Quebec ministry of health [1](#jia225034-bib-0001){ref-type="ref"}, [19](#jia225034-bib-0019){ref-type="ref"}, [23](#jia225034-bib-0023){ref-type="ref"}.

We observed a significant association between increasing age with early ART initiation in the bivariate analysis, which decreased to marginal significance when considering other covariates in the multivariable model. In contrast, Cescon *et al*. reported late ART initiation in older adult participants from the CANOC [29](#jia225034-bib-0029){ref-type="ref"}. This difference may be due to our analysis focusing on patients diagnosed during primary HIV infection and the differing study period, 1996 to 2015 versus 2000 to 2012 for the CANOC study. Our finding, however, is consistent with a large prospective study (Swiss HIV Cohort) where younger age was associated with delayed ART initiation [42](#jia225034-bib-0042){ref-type="ref"}. Of note, in both the CANOC and Swiss studies, early ART initiation was defined based on CD4 counts, whereas our study defined ART initiation as occurring within six months of the PHI diagnosis/the baseline visit. We observed an independent association of early ART initiation with lower CD4 counts, which is comparable with CANOC study findings and has been associated with faster disease progression.

Degroote *et al*. have reported on the associations of socio‐economic, behavioural and clinical factors with health‐related quality of life in HIV‐infected individuals in Belgium [43](#jia225034-bib-0043){ref-type="ref"}. They reported incapacity to work as an important determinant of patient outcomes highlighting the role of socio‐economic factors. Similarly, Kesselring *et al*. linked lower socio‐economic status with late ART initiation in 61 participants of the ENGAGE Cohort Study in British Columbia, Canada [44](#jia225034-bib-0044){ref-type="ref"}. These results are consistent with our observation of having a paid employment contributing to early ART initiation during PHI. We, however, did not include annual income in the multivariable model due to its significant association with employment status (χ^2^ *p* \< 0.001 and Cramer\'s V = 0.697; *p* \< 0.001; Data not shown). Employment is considered a component of economic status, and plays an important role in an individual\'s overall health and access to healthcare [45](#jia225034-bib-0045){ref-type="ref"}. Our findings indicate unemployment status as a potential barrier to care despite the context of universal care including ART medication where only a maximum copayment of CAN \$87.16 per month is expected for those not on social welfare and are covered by the provincial insurance. Interestingly, we observed delayed ART initiation in those not having a paid employment and this group included those on social welfare. In similar settings such as Spain where no copayment is required, Perez‐Molina *et al*. also reported an association of lower socio‐economic status with late ART initiation [46](#jia225034-bib-0046){ref-type="ref"}. In the resource‐limited settings with no universal health coverage such as Uganda, improved employment and schooling outcomes were reported in households of HIV‐infected adults with high CD4 counts owing to early initiation of ART [47](#jia225034-bib-0047){ref-type="ref"}. Therefore, employment and socio‐economic status should be considered if a better control of HIV epidemic is expected. Inclusion of social support programs into the HIV care centres focusing on individuals with lower socio‐economic status and/or without employment may reduce such barriers to early ART initiation.

Boyer *et al*. recently described early ART initiation rates and associated factors in 514 HIV‐infected individuals enrolled in a universal test and treat cluster randomized trial in South Africa [48](#jia225034-bib-0048){ref-type="ref"}. They reported an early ART initiation rate of 88% from 2012 to 2015, which is consistent with our result for a similar time period. Similarly, in both studies lower CD4 T‐cell count was associated with early ART initiation. They also reported an association between early ART initiation and having a regular sexual partner. On the other hand, we asked about the number of sexual partners in the past three months, which did not show an association with early ART initiation. These differences may be due to the way the question was asked, and the predominant female participants in their South African study (70.4%) compared to a small proportion of our study participants (4.0%). In addition, we report time trends in early ART initiation resembling a V‐shaped curve over the years from 1996 to 2015. The trends in ART initiation reflect evolving treatment recommendations over time: "treat early and treat hard" in the mid‐1990s, changing to initiation only when CD4 \< 200 cells/mm^3^, and the current practice of treating HIV irrespective of CD4 count [1](#jia225034-bib-0001){ref-type="ref"}, [23](#jia225034-bib-0023){ref-type="ref"}, [49](#jia225034-bib-0049){ref-type="ref"}, [50](#jia225034-bib-0050){ref-type="ref"}. Due to the recognition of long‐term toxicities of ART including lipodystrophy and the potential for the development of drug resistance, treatment guidelines recommended treatment in asymptomatic patients only until their CD4 counts declined to below 200 [51](#jia225034-bib-0051){ref-type="ref"}, [52](#jia225034-bib-0052){ref-type="ref"}. With recent advancements in antiretroviral drug regimens with limited toxicity and higher efficacy, guidelines now recommend treatment initiation regardless of CD4 counts [1](#jia225034-bib-0001){ref-type="ref"}, [19](#jia225034-bib-0019){ref-type="ref"}.

ART initiation in this cohort was also independently associated with type of care centre; that is participants at UMC versus CMC were more likely to initiate ART within six months (aOR: 2.03; 95% CI: 1.06, 3.90). However, when ART initiation was defined as within one year of baseline visit, no difference between the two clinical settings was observed (Results not shown). This unexpected finding also led us to explore possible differences in participant characteristics in these two settings. Participants seeking care at the CMCs did not differ from those seeking care at the UMCs in terms of age and CD4:CD8 ratio (Results not shown). However, participants at UMCs versus CMCs presented with a lower median CD4 count (*p* = 0.044), which could have led these participants to initiate early ART. Such statistical differences between median CD4 counts in CMCs versus UMCs may not be clinically meaningful as very limited opportunistic infections or comorbidities may develop at a difference of 33 CD4 cells/μl). Another possible explanation is that patients who are acutely ill tend to go to the hospital emergency rooms, where referral is biased to the ambulatory follow‐up in hospitals. Therefore, symptomatic presentation may be important for understanding this difference. The presence of AIDS‐defining diseases as well as diagnoses such as TB, hepatitis B, hepatitis C, lymphoma and HIV‐associated chronic comorbidities such as renal disease may have influenced decisions to initiate ART. Therefore, missing information about these concomitant illnesses may have limited our capacity to examine the presence of these factors in the increased likelihood of early ART initiation in UMCs. Nonetheless, the frequency of the AIDS‐defining illness is extremely rare during the initial years of infection and the prevalence of TB, hepatitis C and hepatitis B are very low in men having sex with men in the province of Quebec. This difference in early ART initiation by type of centre, however, was independent of socio‐demographic factors. In addition, higher plasma VL and lower CD4 counts have previously been shown by our group to be associated with severe clinical presentation [53](#jia225034-bib-0053){ref-type="ref"}, [54](#jia225034-bib-0054){ref-type="ref"}. Another possible explanation requiring further insight is the comparatively more institutional nature of the UMCs with different practice patterns of physicians and/or more support services for patients. Similarly, there may have been less concern for lipodystrophic changes induced by ART [55](#jia225034-bib-0055){ref-type="ref"} and its social image by the institutional physicians. In addition, patients might have been treated earlier at UMCs by participating in the clinical trials and possibly academic physicians were more likely to follow most recent research findings rather than therapeutic guidelines. Therefore, a better description of the clinical site attributes, medical provider training and treatment‐related knowledge and beliefs could help to explain this finding. Besides quantitative research, a qualitative approach to further explore the barriers to early treatment in the patients in these two types of centres can be useful.

Our study has several limitations which need to be considered while interpreting the results. First, our study population was predominantly comprised of MSM which limits the generalizability of study findings. The inclusion of only 14 female participants limited our analysis on the potential influence of gender on ART initiation in this study. However, the MSM group represents the majority (53%) of persons living with HIV in Canada despite the presence of small regional variations [56](#jia225034-bib-0056){ref-type="ref"}. Among 249 new HIV cases in Quebec during the year 2015, 76% were MSM [57](#jia225034-bib-0057){ref-type="ref"}. Furthermore, among the key HIV populations in Canada, the incidence of HIV has remained significantly higher and stable in the MSM group over the last decade. Therefore, such findings have important implications in Canada as well as for countries with similar HIV epidemics. Furthermore, it is unknown how representative participants in the Montreal study are of patients experiencing PHI. We have no information on non‐participation to help inform presence of a selection bias. Since, 63.4% of the total study participants (n = 549) contributed to the current analysis, we compared age, sex and income distribution of this group (n = 348) with the rest (n = 201) to evaluate potential selection bias. This analysis showed a similar age (*p* = 0.845), sex (*p* = 0.131) and income distribution (*p* = 0.099) among the two groups. Moreover, information was missing for some of the participants in clinical and socio‐demographic characteristics which did not allow for multivariable modelling. Similarly, information on the number of sexual partners in the last three months was asked as a close‐ended question with limited number of categories due to sensitivity of the information and to increase response. In addition, information on geographic factors was not collected due to ethical concerns, limiting our analysis regarding distance to care. Therefore, there could be residual confounding due to lacking/missing information and unavailability of clinically important variables such as mental health status. This study also did not include information on signs and symptoms which could be a confounding factor for the association between early ART initiation and type of care centre. The substantial fluctuation in the ART initiation rates over the years in our study may be influenced by data artefacts, which may have been mitigated by categorizing year into three‐year intervals. Finally, our sample size did not allow performing analyses stratified by type of care centre to assess the possible effect modification on socio‐economic status and early ART initiation. Such limitations need to be considered in future large scale studies.

Nevertheless, our study findings suggest the presence of a health inequity in access to healthcare even in the context of universal access to care. Besides overcoming the challenges in early diagnosis of HIV infection [58](#jia225034-bib-0058){ref-type="ref"}, early ART initiation represents an effective strategy in reducing morbidity and mortality among HIV‐infected persons [59](#jia225034-bib-0059){ref-type="ref"}, [60](#jia225034-bib-0060){ref-type="ref"}. Nearly a decade ago, our group was among the first proponents of ART initiation at early stages of infection based on our knowledge of local transmission dynamics and foreseeable benefits for the individual and community [5](#jia225034-bib-0005){ref-type="ref"}, [61](#jia225034-bib-0061){ref-type="ref"}, [62](#jia225034-bib-0062){ref-type="ref"}. With recent guidelines recommending treatment for all at the time of HIV diagnosis, monitoring HIV clinical cohorts for inequities in access to early ART would be important to further document the nature and persistence of this phenomenon. Of note, the Montreal PHI Study also represents a unique cohort, where participants treated early could also be invited to participate in future HIV eradication studies.

5. Conclusions {#jia225034-sec-0017}
==============

Globally, calendar year, prognostic factors and socio‐economic characteristics were associated with early ART initiation during primary HIV infection. An ongoing consideration of socio‐economic characteristics is important as interventions are developed to achieve the UNAIDS goals of 90‐90‐90 and ultimately curtail the HIV epidemic.
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